Assessment of mitral valve function in children and young adults with hypertrophic cardiomyopathy using three-dimensional echocardiography

The objective of this study was to assess papillary muscle (PM) and mitral valve (MV) structure and function in children and young adults with mild and moderate hypertrophic cardiomyopathy (HCM) using real-time three-dimensional echocardiography (3DE) and to correlate them with HCM related adverse o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cardiology 2021-06, Vol.332, p.182-188
Hauptverfasser: Joseph, Navya, Craft, Mary, Mill, LuAnn, Erickson, Christopher C., Danford, David A., Kutty, Shelby, Li, Ling
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 188
container_issue
container_start_page 182
container_title International journal of cardiology
container_volume 332
creator Joseph, Navya
Craft, Mary
Mill, LuAnn
Erickson, Christopher C.
Danford, David A.
Kutty, Shelby
Li, Ling
description The objective of this study was to assess papillary muscle (PM) and mitral valve (MV) structure and function in children and young adults with mild and moderate hypertrophic cardiomyopathy (HCM) using real-time three-dimensional echocardiography (3DE) and to correlate them with HCM related adverse outcomes. Transthoracic research 3DE was performed in HCM patients and controls matched for age and gender. Anterolateral and posteromedial PM mass, apical displacement of anterolateral PM, and left ventricular (LV) mass were measured and indexed to body surface area. The MV annulus and leaflet structure and function were analyzed. Individual PMs were manually planimetered by tracing the endocardial borders on each mid systole frame, taking care to distinguish PMs as distinct from the LV wall. Apical PM displacement was expressed as ratio of the distance between the apex and the base of the anterolateral PM to the entire length of the LV lateral wall (APL index). All 3DE measurements were correlated to adverse outcomes. Forty subjects were studied, including 20 HCM patients (age 18.1 ± 9.6 years, 16 male and 4 female), and 20 controls (18.2 ± 9.6 years, 16 male and 4 female). The indexed LV mass in HCM was 74.8 ± 25.8 g/m2 compared to 50.8 ± 12.4 g/m2 in controls (p = 0.001). The anterolateral, posteromedial and combined PM mass were 3.1 ± 2.2 g/m2, 1.7 ± 1.2 g/m2 and 4.9 ± 2.7 g/m2 in HCM, in contrast to respective measurements of 1.1 ± 0.6 g/m2, 1.2 ± 0.6 g/m2 and 2.3 ± 0.8 g/m2 in controls (p < 0.001, p = 0.062, and p < 0.001, respectively). The mitral valve annular parameters (annulus circumference, height and area) in HCM were not significantly different from controls. The APL index in HCM was less than in controls (0.44 ± 0.07 vs. 0.55 ± 0.04, p < 0.001). The LV lateral wall length and LV mass correlated with adverse HCM outcomes, while the APL index and PM total mass were not associated with adverse events. It is feasible to evaluate PM muscles and MV annulus geometry in children and young adults with HCM using 3DE. The morphologic and functional changes of anterolateral PM may occur in the absence of MV annulus changes. Prospective validation will be required to determine if LV lateral wall length and LV mass may be used as predictors of adverse events. •It is feasible to assess papillary muscle and mitral valve structure in hypertrophic cardiomyopathy on 3D echocardiography•The ratio of the anterolateral papillary muscle insertion length to the LV latera
doi_str_mv 10.1016/j.ijcard.2021.03.040
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2504348884</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527321005441</els_id><sourcerecordid>2504348884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-1e3ffb8ddc9b3b3ea1392e314951a358410dfd047d08b53ea3bda919b2b64bc23</originalsourceid><addsrcrecordid>eNp9kc1O3TAQha2Kqlxo36CqvOwmwY6dm2SDhBAtSEhs2rXlnwnxVWKntnNRXoGnrq9Cu2Q1i_nOnJk5CH2lpKSE7q8OpT1oGUxZkYqWhJWEkw9oR9uGF7Sp-RnaZawp6qph5-gixgMhhHdd-wmdM9bULJM79HoTI8Q4gUvY93iyKcgRH-V4BNwvTifrHbYO68GOJoDD0hm8-sU9Y2mWMUX8YtOAh3WGkIKfB6vxaSvrp9XPMg0rXqLNdBoCQGFsdop5ZjYBPfgNfQ5yHtbP6GMvxwhf3uol-v3j7tftffH49PPh9uax0GxfpYIC63vVGqM7xRQDSVlXAaO8q6lkdcspMb0hvDGkVXXuM2VkRztVqT1XumKX6Ps2dw7-zwIxiclGDeMoHfgliqomnPG2bXlG-Ybq4GMM0Is52EmGVVAiTimIg9hSEKcUBGEip5Bl394cFjWB-S_69_YMXG8A5DuPFoKI2oLTYGwAnYTx9n2Hv3ihnxU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2504348884</pqid></control><display><type>article</type><title>Assessment of mitral valve function in children and young adults with hypertrophic cardiomyopathy using three-dimensional echocardiography</title><source>Elsevier ScienceDirect Journals</source><creator>Joseph, Navya ; Craft, Mary ; Mill, LuAnn ; Erickson, Christopher C. ; Danford, David A. ; Kutty, Shelby ; Li, Ling</creator><creatorcontrib>Joseph, Navya ; Craft, Mary ; Mill, LuAnn ; Erickson, Christopher C. ; Danford, David A. ; Kutty, Shelby ; Li, Ling</creatorcontrib><description>The objective of this study was to assess papillary muscle (PM) and mitral valve (MV) structure and function in children and young adults with mild and moderate hypertrophic cardiomyopathy (HCM) using real-time three-dimensional echocardiography (3DE) and to correlate them with HCM related adverse outcomes. Transthoracic research 3DE was performed in HCM patients and controls matched for age and gender. Anterolateral and posteromedial PM mass, apical displacement of anterolateral PM, and left ventricular (LV) mass were measured and indexed to body surface area. The MV annulus and leaflet structure and function were analyzed. Individual PMs were manually planimetered by tracing the endocardial borders on each mid systole frame, taking care to distinguish PMs as distinct from the LV wall. Apical PM displacement was expressed as ratio of the distance between the apex and the base of the anterolateral PM to the entire length of the LV lateral wall (APL index). All 3DE measurements were correlated to adverse outcomes. Forty subjects were studied, including 20 HCM patients (age 18.1 ± 9.6 years, 16 male and 4 female), and 20 controls (18.2 ± 9.6 years, 16 male and 4 female). The indexed LV mass in HCM was 74.8 ± 25.8 g/m2 compared to 50.8 ± 12.4 g/m2 in controls (p = 0.001). The anterolateral, posteromedial and combined PM mass were 3.1 ± 2.2 g/m2, 1.7 ± 1.2 g/m2 and 4.9 ± 2.7 g/m2 in HCM, in contrast to respective measurements of 1.1 ± 0.6 g/m2, 1.2 ± 0.6 g/m2 and 2.3 ± 0.8 g/m2 in controls (p &lt; 0.001, p = 0.062, and p &lt; 0.001, respectively). The mitral valve annular parameters (annulus circumference, height and area) in HCM were not significantly different from controls. The APL index in HCM was less than in controls (0.44 ± 0.07 vs. 0.55 ± 0.04, p &lt; 0.001). The LV lateral wall length and LV mass correlated with adverse HCM outcomes, while the APL index and PM total mass were not associated with adverse events. It is feasible to evaluate PM muscles and MV annulus geometry in children and young adults with HCM using 3DE. The morphologic and functional changes of anterolateral PM may occur in the absence of MV annulus changes. Prospective validation will be required to determine if LV lateral wall length and LV mass may be used as predictors of adverse events. •It is feasible to assess papillary muscle and mitral valve structure in hypertrophic cardiomyopathy on 3D echocardiography•The ratio of the anterolateral papillary muscle insertion length to the LV lateral wall length is reduced in HCM•Anterolateral papillary muscle changes preceded mitral valve annulus changes, while LV mass correlated with outcomes</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2021.03.040</identifier><identifier>PMID: 33753187</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Hypertrophic cardiomyopathy ; Mitral valve ; Pediatrics ; Risk stratification</subject><ispartof>International journal of cardiology, 2021-06, Vol.332, p.182-188</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-1e3ffb8ddc9b3b3ea1392e314951a358410dfd047d08b53ea3bda919b2b64bc23</citedby><cites>FETCH-LOGICAL-c362t-1e3ffb8ddc9b3b3ea1392e314951a358410dfd047d08b53ea3bda919b2b64bc23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0167527321005441$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33753187$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Joseph, Navya</creatorcontrib><creatorcontrib>Craft, Mary</creatorcontrib><creatorcontrib>Mill, LuAnn</creatorcontrib><creatorcontrib>Erickson, Christopher C.</creatorcontrib><creatorcontrib>Danford, David A.</creatorcontrib><creatorcontrib>Kutty, Shelby</creatorcontrib><creatorcontrib>Li, Ling</creatorcontrib><title>Assessment of mitral valve function in children and young adults with hypertrophic cardiomyopathy using three-dimensional echocardiography</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>The objective of this study was to assess papillary muscle (PM) and mitral valve (MV) structure and function in children and young adults with mild and moderate hypertrophic cardiomyopathy (HCM) using real-time three-dimensional echocardiography (3DE) and to correlate them with HCM related adverse outcomes. Transthoracic research 3DE was performed in HCM patients and controls matched for age and gender. Anterolateral and posteromedial PM mass, apical displacement of anterolateral PM, and left ventricular (LV) mass were measured and indexed to body surface area. The MV annulus and leaflet structure and function were analyzed. Individual PMs were manually planimetered by tracing the endocardial borders on each mid systole frame, taking care to distinguish PMs as distinct from the LV wall. Apical PM displacement was expressed as ratio of the distance between the apex and the base of the anterolateral PM to the entire length of the LV lateral wall (APL index). All 3DE measurements were correlated to adverse outcomes. Forty subjects were studied, including 20 HCM patients (age 18.1 ± 9.6 years, 16 male and 4 female), and 20 controls (18.2 ± 9.6 years, 16 male and 4 female). The indexed LV mass in HCM was 74.8 ± 25.8 g/m2 compared to 50.8 ± 12.4 g/m2 in controls (p = 0.001). The anterolateral, posteromedial and combined PM mass were 3.1 ± 2.2 g/m2, 1.7 ± 1.2 g/m2 and 4.9 ± 2.7 g/m2 in HCM, in contrast to respective measurements of 1.1 ± 0.6 g/m2, 1.2 ± 0.6 g/m2 and 2.3 ± 0.8 g/m2 in controls (p &lt; 0.001, p = 0.062, and p &lt; 0.001, respectively). The mitral valve annular parameters (annulus circumference, height and area) in HCM were not significantly different from controls. The APL index in HCM was less than in controls (0.44 ± 0.07 vs. 0.55 ± 0.04, p &lt; 0.001). The LV lateral wall length and LV mass correlated with adverse HCM outcomes, while the APL index and PM total mass were not associated with adverse events. It is feasible to evaluate PM muscles and MV annulus geometry in children and young adults with HCM using 3DE. The morphologic and functional changes of anterolateral PM may occur in the absence of MV annulus changes. Prospective validation will be required to determine if LV lateral wall length and LV mass may be used as predictors of adverse events. •It is feasible to assess papillary muscle and mitral valve structure in hypertrophic cardiomyopathy on 3D echocardiography•The ratio of the anterolateral papillary muscle insertion length to the LV lateral wall length is reduced in HCM•Anterolateral papillary muscle changes preceded mitral valve annulus changes, while LV mass correlated with outcomes</description><subject>Hypertrophic cardiomyopathy</subject><subject>Mitral valve</subject><subject>Pediatrics</subject><subject>Risk stratification</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kc1O3TAQha2Kqlxo36CqvOwmwY6dm2SDhBAtSEhs2rXlnwnxVWKntnNRXoGnrq9Cu2Q1i_nOnJk5CH2lpKSE7q8OpT1oGUxZkYqWhJWEkw9oR9uGF7Sp-RnaZawp6qph5-gixgMhhHdd-wmdM9bULJM79HoTI8Q4gUvY93iyKcgRH-V4BNwvTifrHbYO68GOJoDD0hm8-sU9Y2mWMUX8YtOAh3WGkIKfB6vxaSvrp9XPMg0rXqLNdBoCQGFsdop5ZjYBPfgNfQ5yHtbP6GMvxwhf3uol-v3j7tftffH49PPh9uax0GxfpYIC63vVGqM7xRQDSVlXAaO8q6lkdcspMb0hvDGkVXXuM2VkRztVqT1XumKX6Ps2dw7-zwIxiclGDeMoHfgliqomnPG2bXlG-Ybq4GMM0Is52EmGVVAiTimIg9hSEKcUBGEip5Bl394cFjWB-S_69_YMXG8A5DuPFoKI2oLTYGwAnYTx9n2Hv3ihnxU</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Joseph, Navya</creator><creator>Craft, Mary</creator><creator>Mill, LuAnn</creator><creator>Erickson, Christopher C.</creator><creator>Danford, David A.</creator><creator>Kutty, Shelby</creator><creator>Li, Ling</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210601</creationdate><title>Assessment of mitral valve function in children and young adults with hypertrophic cardiomyopathy using three-dimensional echocardiography</title><author>Joseph, Navya ; Craft, Mary ; Mill, LuAnn ; Erickson, Christopher C. ; Danford, David A. ; Kutty, Shelby ; Li, Ling</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-1e3ffb8ddc9b3b3ea1392e314951a358410dfd047d08b53ea3bda919b2b64bc23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Hypertrophic cardiomyopathy</topic><topic>Mitral valve</topic><topic>Pediatrics</topic><topic>Risk stratification</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joseph, Navya</creatorcontrib><creatorcontrib>Craft, Mary</creatorcontrib><creatorcontrib>Mill, LuAnn</creatorcontrib><creatorcontrib>Erickson, Christopher C.</creatorcontrib><creatorcontrib>Danford, David A.</creatorcontrib><creatorcontrib>Kutty, Shelby</creatorcontrib><creatorcontrib>Li, Ling</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joseph, Navya</au><au>Craft, Mary</au><au>Mill, LuAnn</au><au>Erickson, Christopher C.</au><au>Danford, David A.</au><au>Kutty, Shelby</au><au>Li, Ling</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of mitral valve function in children and young adults with hypertrophic cardiomyopathy using three-dimensional echocardiography</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>332</volume><spage>182</spage><epage>188</epage><pages>182-188</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><abstract>The objective of this study was to assess papillary muscle (PM) and mitral valve (MV) structure and function in children and young adults with mild and moderate hypertrophic cardiomyopathy (HCM) using real-time three-dimensional echocardiography (3DE) and to correlate them with HCM related adverse outcomes. Transthoracic research 3DE was performed in HCM patients and controls matched for age and gender. Anterolateral and posteromedial PM mass, apical displacement of anterolateral PM, and left ventricular (LV) mass were measured and indexed to body surface area. The MV annulus and leaflet structure and function were analyzed. Individual PMs were manually planimetered by tracing the endocardial borders on each mid systole frame, taking care to distinguish PMs as distinct from the LV wall. Apical PM displacement was expressed as ratio of the distance between the apex and the base of the anterolateral PM to the entire length of the LV lateral wall (APL index). All 3DE measurements were correlated to adverse outcomes. Forty subjects were studied, including 20 HCM patients (age 18.1 ± 9.6 years, 16 male and 4 female), and 20 controls (18.2 ± 9.6 years, 16 male and 4 female). The indexed LV mass in HCM was 74.8 ± 25.8 g/m2 compared to 50.8 ± 12.4 g/m2 in controls (p = 0.001). The anterolateral, posteromedial and combined PM mass were 3.1 ± 2.2 g/m2, 1.7 ± 1.2 g/m2 and 4.9 ± 2.7 g/m2 in HCM, in contrast to respective measurements of 1.1 ± 0.6 g/m2, 1.2 ± 0.6 g/m2 and 2.3 ± 0.8 g/m2 in controls (p &lt; 0.001, p = 0.062, and p &lt; 0.001, respectively). The mitral valve annular parameters (annulus circumference, height and area) in HCM were not significantly different from controls. The APL index in HCM was less than in controls (0.44 ± 0.07 vs. 0.55 ± 0.04, p &lt; 0.001). The LV lateral wall length and LV mass correlated with adverse HCM outcomes, while the APL index and PM total mass were not associated with adverse events. It is feasible to evaluate PM muscles and MV annulus geometry in children and young adults with HCM using 3DE. The morphologic and functional changes of anterolateral PM may occur in the absence of MV annulus changes. Prospective validation will be required to determine if LV lateral wall length and LV mass may be used as predictors of adverse events. •It is feasible to assess papillary muscle and mitral valve structure in hypertrophic cardiomyopathy on 3D echocardiography•The ratio of the anterolateral papillary muscle insertion length to the LV lateral wall length is reduced in HCM•Anterolateral papillary muscle changes preceded mitral valve annulus changes, while LV mass correlated with outcomes</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33753187</pmid><doi>10.1016/j.ijcard.2021.03.040</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-5273
ispartof International journal of cardiology, 2021-06, Vol.332, p.182-188
issn 0167-5273
1874-1754
language eng
recordid cdi_proquest_miscellaneous_2504348884
source Elsevier ScienceDirect Journals
subjects Hypertrophic cardiomyopathy
Mitral valve
Pediatrics
Risk stratification
title Assessment of mitral valve function in children and young adults with hypertrophic cardiomyopathy using three-dimensional echocardiography
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T22%3A55%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20mitral%20valve%20function%20in%20children%20and%20young%20adults%20with%20hypertrophic%20cardiomyopathy%20using%20three-dimensional%20echocardiography&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Joseph,%20Navya&rft.date=2021-06-01&rft.volume=332&rft.spage=182&rft.epage=188&rft.pages=182-188&rft.issn=0167-5273&rft.eissn=1874-1754&rft_id=info:doi/10.1016/j.ijcard.2021.03.040&rft_dat=%3Cproquest_cross%3E2504348884%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2504348884&rft_id=info:pmid/33753187&rft_els_id=S0167527321005441&rfr_iscdi=true